Purinex, Inc

R. Bruner, S. Carr
{"title":"Purinex, Inc","authors":"R. Bruner, S. Carr","doi":"10.1108/case.darden.2016.000244","DOIUrl":null,"url":null,"abstract":"In June 2004 Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, expected to secure a partnership with a major pharmaceutical company sometime in the next four to 12 months. That partnership, if secured, would enable Purinex to develop one of its leading compounds as a drug. The company, however, had no sales or earnings and only 11 months of cash on hand. The student must assess whether the company should attempt to secure financing now or wait until it consummated a partnership deal. The tasks for the student include evaluating the probabilities that collaboration with a pharmaceutical company would actually happen; determining whether the company stay above water until such occurred; and analyzing the other risks to the company under these circumstances. Excerpt UVA-F-1491 Version 4.2 PURINEX, INC. To lead the world in discovering, developing & commercializing novel therapeutic compounds acting on the purine receptors in order to save and improve patients' lives. —Company mission statement In June 2004, Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, had reached a turning point. Sometime in the next four to 12 months, the company stood an excellent chance of securing a partnership with a major pharmaceutical company. That partnership, if secured, would enable Purinex to develop one of its leading compounds into a drug for the treatment of one of the world's deadliest and most widespread diseases. The company had no sales or earnings, however, and there was only enough cash on hand to last 11 months. . . .","PeriodicalId":174643,"journal":{"name":"Entrepreneurship Educator: Courses","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Entrepreneurship Educator: Courses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1108/case.darden.2016.000244","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In June 2004 Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, expected to secure a partnership with a major pharmaceutical company sometime in the next four to 12 months. That partnership, if secured, would enable Purinex to develop one of its leading compounds as a drug. The company, however, had no sales or earnings and only 11 months of cash on hand. The student must assess whether the company should attempt to secure financing now or wait until it consummated a partnership deal. The tasks for the student include evaluating the probabilities that collaboration with a pharmaceutical company would actually happen; determining whether the company stay above water until such occurred; and analyzing the other risks to the company under these circumstances. Excerpt UVA-F-1491 Version 4.2 PURINEX, INC. To lead the world in discovering, developing & commercializing novel therapeutic compounds acting on the purine receptors in order to save and improve patients' lives. —Company mission statement In June 2004, Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, had reached a turning point. Sometime in the next four to 12 months, the company stood an excellent chance of securing a partnership with a major pharmaceutical company. That partnership, if secured, would enable Purinex to develop one of its leading compounds into a drug for the treatment of one of the world's deadliest and most widespread diseases. The company had no sales or earnings, however, and there was only enough cash on hand to last 11 months. . . .
Purinex公司
2004年6月,Purinex制药公司,一家拥有几种临床和商业前景良好的药物正在开发的制药公司,预计将在未来4到12个月内与一家大型制药公司建立合作伙伴关系。如果这一合作关系得到保障,Purinex将能够开发出一种领先的化合物作为药物。然而,该公司没有销售或盈利,手头只有11个月的现金。学生必须评估公司是否应该现在就尝试获得融资,还是等到它完成了一笔合伙交易。学生的任务包括评估与制药公司合作的可能性;确定公司是否在这种情况发生之前一直处于困境;并分析在这种情况下公司面临的其他风险。摘录UVA-F-1491版本4.2 PURINEX, INC。引领世界发现、开发和商业化作用于嘌呤受体的新型治疗化合物,以挽救和改善患者的生命。-公司使命2004年6月,Purinex, Inc.,一家正在开发几种临床和商业上有前景的药物的制药公司,到达了一个转折点。在未来4到12个月的某个时候,该公司很有可能与一家大型制药公司建立合作关系。如果双方达成合作,Purinex将有能力将其领先的一种化合物开发成一种药物,用于治疗世界上最致命、传播最广泛的疾病之一。然而,该公司没有销售或盈利,手头的现金仅够维持11个月. . . .
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信